The Art and Science of Sequencing in Multiple Myeloma
Release Date: March 31, 2016
Expiration Date: March 31, 2017
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
The recent pace of advancements in multiple myeloma (MM) treatment planning and care has had no precedent. New clinical insights regarding clonal evolution of MM, as well as who should be treated and when, staging and risk assessment for newly diagnosed patients, monitoring of responses, comparative efficacy of combination regimens, the care and management of elderly or frail patients and strategies for relapsed/refractory disease, as well as the introduction of four new therapeutics into the armamentarium in 2015, have all contributed to a paradigm shift in how this disease is managed today. With new clinical insights and new drugs and combination regimens, the challenge for today’s practitioner is navigating the sequencing of highly effective therapies in such a manner so as to ensure the achievement of the most rapid, deepest, and durable responses to therapy while utilizing the most tolerable approaches predicated on individual patient-specific, disease-specific, and treatment-specific considerations while preserving future options. Join world-leading expert and Managing Myeloma faculty member Noopur Raje, MD, in a discussion of the art and science of treatment sequencing for MM throughout the life cycle of the disease in 2016.
This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in the management of multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Outline the rationale behind treatment sequencing in patients with multiple myeloma, focusing on how approvals of new agents and regimens have impacted sequencing in recent years
- Identify recommendations for sequencing of treatment in otherwise healthy patients with multiple myeloma throughout the life cycle of the disease
- Describe how treatment sequencing must be adapted in the fit, intermediate fit, and frail elderly patients with multiple myeloma
The Art and Science of Sequencing in Multiple Myeloma – Noopur Raje, MD
Instructions for Participation and Credit
This activity is eligible for credit through March 31, 2017. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Noopur Raje, MD
Director, Multiple Myeloma Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Dr. Noopur Raje received her medical degree from B.J. Medical College, Pune University, India. She has trained in internal medicine at Massachusetts General Hospital (MGH) and has completed a fellowship in hematology and medical oncology at the Dana-Farber Cancer Institute, Boston. Dr. Raje has a joint faculty appointment at MGH and Dana-Farber Cancer Institute. She is an Associate Professor of Medicine at Harvard Medical School and is the Director of the Multiple Myeloma Program, Medical Oncology, at MGH. As a hematologist/oncologist at MGH, Dr. Raje’s primary focus is in multiple myeloma and related research. Her laboratory focuses on bone biology and the development of novel therapeutics for multiple myeloma, as well as identifying and validating novel targets and translating them into clinical trials.
Dr. Raje is a member of the American Medical Association, America Society of Hematology, American Society of Clinical Oncology, and American Association of Cancer Research, she is also an ad hoc reviewer for several journals including Blood, Clinical Cancer Research, Leukemia, and the American Journal of Hematology. Dr. Raje is the recipient of several awards and has published extensively in the field of multiple myeloma research. Her hope is to continue pursuing laboratory and clinical research in the area of multiple myeloma with the goal of translating her efforts to the improvement of patients’ lives.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-16-070-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Noopur Raje has received honoraria related to speakers’ bureau activities from Amgen Inc., Celgene Corporation, and Onyx. She has received grant support related to research activities from Eli Lilly and Company.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, and Eugene R. Tombler, PhD, FACME, Medical Director, Oncology, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Dr. Raje has indicated that she does not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Raje has indicated that she does not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology.
©2016 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.